Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| LGND | 8-K | neutral | 4/10 | Ligand Pharmaceuticals acquired royalty and milestone payment rights on Santen's Ryjunea (a pediatric myopia treatment a | Sep 22, 2026 |
| VKTX | 8-K | bullish | 7/10 | Viking Therapeutics announced positive topline results from its VK2735-102 maintenance study, demonstrating that patient | Sep 22, 2026 |
| TNXP | 8-K | bullish | 5/10 | Tonix Pharmaceuticals announced a second major managed Medicare payer agreement for TONMYA, effective immediately, addin | Sep 22, 2026 |
| CYPH | 8-K | neutral | 4/10 | Cypherpunk Technologies appointed Amanda Fabiano, a veteran digital asset mining executive, to its board of directors. T | Sep 22, 2026 |
| ZBIO | PRESS-RELEASE | neutral | 4/10 | Zenas BioPharma announced upcoming presentations of new data from the Phase 3 INDIGO open-label extension of obexelimab | Sep 22, 2026 |
| ELDN | PRESS-RELEASE | bullish | 7/10 | Eledon Pharmaceuticals announced FDA Fast Track designation for tegoprubart in kidney transplantation and presented posi | Sep 22, 2026 |
| MDWD | PRESS-RELEASE | bullish | 4/10 | MediWound received an additional $3.3 million from the U.S. Department of War to develop a room-temperature-stable formu | Sep 22, 2026 |
| CLDX | PRESS-RELEASE | bullish | 7/10 | Celldex reported positive Phase 3 topline results for barzolvolimab in chronic spontaneous urticaria (CSU). Both EMBARQ- | Sep 22, 2026 |
| SNTI | S-3/A | bearish | 6/10 | Senti Biosciences filed Amendment No. 3 to its S-3 shelf registration (File No. 333-296917) as an exhibits-only filing t | Sep 22, 2026 |
| PHAR | 6-K | bullish | 6/10 | Pharming announced positive Phase II topline data for leniolisib in primary immunodeficiencies (PIDs) with immune dysreg | Sep 22, 2026 |
| IMMP | 6-K | neutral | 4/10 | Immutep is changing its ADS ratio from 1 ADS = 10 ordinary shares to 1 ADS = 200 ordinary shares, effective September 28 | Sep 22, 2026 |
| SAFX | EFFECT | bearish | 7/10 | The SEC declared XCF Global's S-3 shelf registration (File No. 333-298933) effective on September 21, 2026. This unlocks | Sep 22, 2026 |
| BNTC | EFFECT | bearish | 5/10 | Benitec Biopharma's shelf registration (File No. 333-298927) on Form S-3 was declared effective by the SEC on September | Sep 22, 2026 |
| PDSB | SC 13D | bullish | 7/10 | Nant Capital LLC, controlled by Dr. Patrick Soon-Shiong, filed a Schedule 13D disclosing a 19.9% beneficial stake in PDS | Sep 21, 2026 |
| IMRN | 6-K | neutral | 4/10 | Immuron Ltd filed a 6-K furnishing a presentation from the Coffee Microcaps Conference. The presentation highlights FY26 | Sep 21, 2026 |
| BKHA | 424B4 | bearish | 7/10 | Black Hawk Acquisition Corp filed a 424B4 prospectus/proxy statement for its Extraordinary General Meeting on October 13 | Sep 21, 2026 |
| ETRA | 3 | neutral | 2/10 | Westlake BioPartners funds and their general partners filed Form 3 initial beneficial ownership statements for Electra T | Sep 21, 2026 |
| MGX | 8-K | neutral | 4/10 | Metagenomi Therapeutics filed a September 2026 corporate presentation under Item 7.01, highlighting its lead hemophilia | Sep 21, 2026 |
| XFOR | SC 13G | neutral | 4/10 | Venrock Healthcare Capital Partners III, L.P. and affiliated entities filed a new Schedule 13G disclosing a 5.6% passive | Sep 21, 2026 |
| MRK | COURT-RULING | neutral | 3/10 | The District of New Jersey denied Cencora's motion for reconsideration of the order lifting the stay of the third-party | Sep 21, 2026 |
| UTHR | CLUSTER | neutral | 4/10 | Chairperson & CEO Martine Rothblatt and EVP & General Counsel Paul Mahon sold a combined ~$12.1M in open-market sales of | Sep 21, 2026 |
| SION | SC 13D/A | bearish | 7/10 | RA Capital Management has filed Amendment No. 2 to its Schedule 13D, reporting a massive reduction in its stake in Sionn | Sep 21, 2026 |
| AMPH | 144 | neutral | 2/10 | William J. Peters, an officer of Amphastar Pharmaceuticals, filed a Form 144 notice of intent to sell 4,139 shares of co | Sep 21, 2026 |
| RNAZ | 3 | neutral | 2/10 | John A. Tattory filed a Form 3 initial statement of beneficial ownership with the SEC, disclosing his role as Interim CF | Sep 21, 2026 |
| PASG | S-4/A | neutral | 5/10 | Passage Bio (PASG) filed an amended S-4 registration statement for its proposed reverse merger with Remix Therapeutics. | Sep 21, 2026 |
| ELVN | CLUSTER | neutral | 2/10 | Two senior executives at Enliven Therapeutics (CMO and CFO) conducted open-market sales totaling ~$323K within a 7-day w | Sep 21, 2026 |
| TYRA | SC 13G | neutral | 4/10 | Biotechnology Value Fund (BVF) and related entities filed a Schedule 13G on September 21, 2026, disclosing a passive 6.1 | Sep 21, 2026 |
| TOMZ | 8-K | neutral | 4/10 | TOMI Environmental Solutions and Carbonium Core mutually terminated their merger agreement, effective September 15, 2026 | Sep 21, 2026 |
| ORKA | CLUSTER | bearish | 5/10 | Five Oruka Therapeutics insiders, including the CEO, COO, General Counsel, Chief Medical Officer, and SVP of Finance, ex | Sep 21, 2026 |
| TOMZ | PRESS-RELEASE | bullish | 6/10 | TOMI Environmental Solutions and Carbonium Core have mutually terminated their June 28, 2026 merger agreement, with each | Sep 21, 2026 |